INS and type 2 diabetes mellitus: Current therapies for T2D are directed toward reducing elevated blood glucose levels by improving insulin sensitivity in partial peripheral tissue, enhancing insulin secretion from the remaining beta cells, and promoting urinary glucose excretion.